Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

X submitted a new drug application (NDA) for NGX-4010 with the U.S. Food and Drug Administration (FDA) in October 2008 for PHN, which is subject to acceptance by the FDA. Additionally, a marketing authorization application (MAA) for NGX-4010 seeking approval for peripheral neuropathic pain is currently under review by the European Medicines Agency (EMEA).

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 is currently in a Phase 1 clinical trial. The objective of the development program for NGX-1998 is to determine its ability to provide protracted pain relief from a single treatment. As a liquid, NGX-1998 is expected to be suitable for areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. NGX-1998 is being developed with the goal of it becoming a product that has the potential to be used by a broad spectrum of the physician population. NGX-1998 was previously studied in two Phase 1 studies in healthy volunteers conducted under an exploratory investigational new drug application.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, possible approval of NeurogesX' product candidates by the FDA or EMEA; estimations of the PDUFA date timing; plans and ability for commercial launch of NGX-4010; the sufficiency of cash resources to fund operations into 2010; plans for, and the potential timing of, establishment of commercialization partnerships in Europe and the United States, and th
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
(Date:7/10/2014)... Using microscopic polymer light resonators that expand in ... Quantum Photonics Laboratory have developed new optical sensors ... Optical sensors are ideal for detecting trace gas ... lightweight nature, and immunity to electromagnetic interference. , ... before, the MIT team conceived an extremely sensitive, ...
(Date:7/10/2014)... Columbia researchers have observed the fractional quantum Hall effect ... of matter can be tuned by an electric field. ... occur when electrons confined to thin sheets are exposed ... collective behavior where thousands of individual electrons behave as ... this effect is well established, many details of this ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... St. Joseph,s Hospital and Medical Center and the University ... agreement to create the Valley Fever Center based at the ... who has more than 30 years of experience in treating ... of Excellence in Tucson in 1996. The center ...
... At the Heart Failure Society of America,s 15th Annual ... System, announced that B-type natriuretic peptide (BNP) may have ... signs of decompensation in advance of acute presentations.   ... and sponsored by Alere Inc., is the first of ...
... Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that ... Cancer Immunotherapy: A Long-Awaited Reality Conference on Thursday, ... Medicine in New York City.  The single-day conference ... stakeholders to engage in discussions, exchange information, and ...
Cached Biology Technology:St. Joseph's Hospital, University of Arizona Create Valley Fever Center in Phoenix 2HABIT Study Highlights Home BNP Testing May Allow for Earlier Interventions and Better Management of Heart Failure Patient 2HABIT Study Highlights Home BNP Testing May Allow for Earlier Interventions and Better Management of Heart Failure Patient 3NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 2NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 3NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 4
(Date:7/11/2014)... The increased risk of kidney injury related to the ... the mass of HES molecules, according to a report ... the International Anesthesia Research Society (IARS). , The "total ... HES on cultured human renal proximal tubule cells (PTCs), ... colleagues of University Hospital Wrzburg, Austria. Other factorssuch ...
(Date:7/11/2014)... Research and Markets has announced the addition ... Analysis Size Share Growth Trends and Forecast to 2019" ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number of ... high level security in both private and public sector. ... and passwords, tokens etc. are vulnerable to attacks. Biometrics ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP has ... Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain ... United States District Court, Middle District of ... behalf of a class consisting of all persons ... securities between December 17, 2013 and May 22, ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... Scientists found that in 14 independent studies, the yields ... other biofuel feedstocks, such as corn, soybean, sorghum, and ... not yet been evaluated exist. According to bioenergy ... a low risk of unintended land use change. Biomass ...
... have developed a novel system for delivery of growth ... diabetic foot ulcers. In their work published in ... of Sciences , the team from the MGH Center ... keratinocyte growth factor (KGF), a protein known to play ...
... year,s Deepwater Horizon oil spill, nearly 800,000 gallons of chemical ... coming out of the wellhead nearly one mile deep in ... assess how well the strategy worked at breaking up oil ... and her colleagues report that a major component of the ...
Cached Biology News:Growth-factor-containing nanoparticles accelerate healing of chronic wounds 2First study of dispersants in Gulf spill suggests a prolonged deepwater fate 2First study of dispersants in Gulf spill suggests a prolonged deepwater fate 3First study of dispersants in Gulf spill suggests a prolonged deepwater fate 4
... an 18 amino acid synthetic peptide whose sequence corresponds to residues ... is (amino to carboxy terminus): M(1) - A - S - ... - S - P - R - D - A - ... may be used for neutralization and control experiments with the polyclonal ...
... Bisulfite Kit enables complete conversion of ... than 6 hours. The highly sensitive ... DNA degradation and a spin-column-based purification ... and reliable results for all downstream ...
... from high throughput synthesis are new and unique ... These products provide a large number (from hundreds ... in a microtube as a mixture or in ... sequence. This is a custom product so RNA ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Biology Products: